首页> 外文期刊>Neuropsychiatric Disease and Treatment >Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review
【24h】

Extended-release divalproex in bipolar and other psychiatric disorders: A comprehensive review

机译:躁郁症和其他精神疾病的缓释双丙戊酸钠:全面综述

获取原文
           

摘要

Abstract: Bipolar disorder can be a devastating disease state for individuals with the disease and also for family members. Proper recognition and treatment is vital to the successful management of this disease state. Through increased community and practitioner awareness, along with efforts to increase awareness for proper assessment, the rate of diagnosed bipolar disorder is increasing. Recent years have brought about the introduction of several new medications with approved indications for the treatment of bipolar disorder. In addition to new agents, traditional mood stabilizing medications have also been released in different formulations to better enhance tolerability without jeopardizing efficacy. One particular product is extended-release divalproex sodium. In the following article, we review the clinical presentation of bipolar disorder, its epidemiology, and the pharmacokinetics and mechanism of action for divalproex. In addition, we specifically review the role of extended-release divalproex in bipolar disorder through a critical analysis of the currently available published primary literature.
机译:摘要:躁郁症对于患有这种疾病的个人以及家庭成员而言,可能是一种毁灭性的疾病。正确的识别和治疗对于成功控制该疾病状态至关重要。通过提高社区和从业者的意识,以及努力提高对正确评估的认识,诊断出的躁郁症的发生率正在增加。近年来,已经引入了几种新药,这些药物已被批准用于治疗躁郁症。除新药外,传统的稳定情绪药物也已以不同的配方发布,以更好地提高耐受性而又不损害疗效。一种特定的产品是缓释双丙戊酸钠。在下面的文章中,我们回顾了躁郁症的临床表现,流行病学以及divalproex的药代动力学和作用机理。此外,我们通过对当前可用的主要文献进行严格的分析,专门审查了缓释双丙戊酸钠在躁郁症中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号